1-      Fattahi, M.J., Sedaghat, F., Malekzadeh, M., Taghipour, M., Ghaderi, A. Endocan serum levels in patients with low- and high-grade meningiomas: does this biomarker have an indicative role? Egyptian Journal of Neurology, Psychiatry and Neurosurgery. 2021, 57(1), 92.

2-      Ghahartars, M., Abtahi, S., Zeinali, Z., Fattahi, M.J., Ghaderi, A. Investigation of tnf-α and il-6 levels in the sera of non-melanoma skin cancer patients. Iranian Biomedical Journal 2021, 25(2), pp. 88–92.

3-      Ghahartars, M., Sedaghat, F., Khajavi, E., Ghaderi, A., Fattahi, M.J. Investigation of IL-17A Serum Levels in Patients with Nonmelanoma Skin Cancer. Dermatology Research and Practice 2021 Jun 18;2021:5540163

4-      Ghahartars, M., Najafzadeh, S., Abtahi, S., Fattahi, M.J., Ghaderi, A. Investigation of Interleukin-27 in the Sera of Nonmelanoma Skin Cancer Patients. Dermatol Res Pract.2018 Nov 19;2018:8321302.

5-      Mardani M, Andishe Tadbir A, Ranjbar MA, Khademi B, Fattahi MJ, Rahbar A. Serum Endostatin Levels in Oral Squamous Cell Carcinoma. Iran J Otorhinolaryngol. 2018 May;30(98):125-130.

6-      Mohammad Javad Fattahi, Hossein Ahmadi, Fahimeh Jafarnezhad-Ansariha, Seyed Shahabeddin Mortazavi-Jahromi, Bernd H.A. Rehm, Salvatore Cuzzocrea, Hidenori Matsuo, Abbas Mirshafiey. Oral administration effects of β-D-mannuronic acid (M2000) on Th17 and regulatory T cells in patients with ankylosing spondylitis. Biomedicine & Pharmacotherapy. 2018; 100: 495–500.

7-      Ahmadi H, Jamshidi AR, Mahmoudi M, Gharibdoost F, Vojdanian M, Fattahi MJ, Rastkari N, Aghazadeh Z, Mirshafiey A. Hematological Improvement of Patients with Active Rheumatoid Arthritis by β-D-Mannuronic Acid (M2000) as a Novel NSAID with Immunosuppressive Property. Iran J Allergy Asthma Immunol. 2017 Oct;16(5):433-442.

8-      Fattahi MJ, Jamshidi AR, Mahmoudi M, Vojdanian M, Yekaninejad MS, Jafarnezhad-Ansariha F, Ahmadi H, Rehm BHA, Matsuo H, Cuzzocrea S, Hosseini M, Hashemi SN, Aghazadeh Z, Mirshafiey A. Evaluation of the efficacy and safety of β-d-mannuronic acid in patients with ankylosing spondylitis: A 12-week randomized, placebo-controlled, phase I/II clinical trial. Int Immunopharmacol. 2018 Jan; 54:112-117.